Month: October 2017
-
Multi-Drug Resistance Antibiotic Developer to Issue IPO
A three year-old company making new antibiotics to treat infections resistant to earlier antibiotics plans to raise some $75 million in its initial public stock offering.
-
Biosimilars Seen Saving U.S. $54 Billion
An analysis of health care costs shows increasing the use of substitute biologic treatments known as biosimilars could save the United States some $54 billion over 10 years.
-
Big Data Analysis Platform for Brainwaves in Development
Two companies in Northern Ireland, U.K. are creating a technology platform applying big data analytics to a collection of brainwaves generated by mobile games for measuring cognitive health.
-
Univ. Lab, Company Broaden Bacterial Vaccine Impact
Researchers from University at Buffalo and a campus spin-off enterprise devised a way to expand the scope of anti-bacterial vaccines, as shown in tests with lab animals.
-
Infographic: World’s Best Employers
In this year’s survey of public companies by Forbes magazine, those from the tech industry are well represented among the best places to work.
-
Company, Foundation Start Multiple Sclerosis Registry
National Multiple Sclerosis Society and the company Corrona LLC are establishing a registry of people with multiple sclerosis in North America to help assess the long-term safety and effectiveness of therapies approved to treat the disorder.
-
Contact Lens Devised to Measure Glaucoma Eye Pressure
Engineers in the U.K. developed a soft contact lens that in a clinical study shows it can reliably track changes in pressure inside the eye, a key factor in glaucoma.
-
Live Skin Bacteria Shown to Control Acne
First results of a clinical trial show a spray-on formulation of live bacteria reduced the amount and severity of acne in people with mild to moderate cases of the condition.
-
Snake-Like Intelligent Robot in Development
An engineering team is creating a self-powered robot that can travel independently like a snake through uneven and cluttered surfaces, such as disaster sites.
-
Lilly, CureVac Partner on RNA Cancer Drugs in $1.8B Deal
Drug maker Eli Lilly and Company and biotechnology company CureVac AG agreed to develop a series of cancer immunotherapies based on CureVac’s messenger RNA technology.